Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Year range
1.
Arq. bras. endocrinol. metab ; 54(6): 572-577, ago. 2010. ilus, tab
Article in Portuguese | LILACS | ID: lil-557855

ABSTRACT

A síndrome de deleção 22q11.2 (SD22q11.2) está associada à alta variabilidade fenotípica, abrangendo o espectro velocardiofacial/síndrome de DiGeorge. Manifestações autoimunes, endocrinológicas e de imunodeficiência vêm sendo relatadas associadas à síndrome. O objetivo deste estudo foi relatar um caso de SD22q11.2 associado à deficiência de IgA e à doença de Graves e rever a literatura visando verificar a frequência dessas alterações na SD22q11.2. Os distúrbios autoimunes, cada vez mais relacionadas a SD22q11.2 e novos fenótipos, vêm sendo incorporadas ao seu espectro clínico. No presente estudo, verificou-se que a doença de Graves associada à SD22q11.2 foi relatada em apenas dezesseis pacientes e quinze descritos na literatura nos últimos 13 anos. Com base na incidência e na amplitude de seu espectro de manifestações já reconhecidas, reforçaram-se os achados da literatura de que a doença de Graves deve ser incluída nas manifestações da SD22q11.2, o que nos levaria a pesquisá-la nos portadores da deleção 22q11.2.


The 22q11.2 deletion syndrome (22q11.2DS) is related to a high phenotypic variability including the velocardiofacial/DiGeorge spectrum. Autoimmune, endocrine and immunodeficiency manifestations have been reportedly associated with the syndrome. The objective of this study was to report a case of 22q11.2DS associated with IgA deficiency and Graves disease and review literature in order to verify the frequency of syndrome alterations. Autoimmune disorders have been increasingly related to 22q11.2DS, and new phenotypes are being incorporated in the clinical spectrum of this syndrome. In our study we found that Graves disease in association with 22q11.2DS was reported in only sixteen patients, and fifteen cases were described in the last 13 years. Based on the incidence and on the amplitude of this recognized spectrum, we reinforce the findings of literature that Graves disease should be included on the 22q11.2DS manifestations, which would lead us to seek it with 22q11.2 deletion patients.


Subject(s)
Child , Humans , Male , /complications , Graves Disease/genetics , IgA Deficiency/genetics , /genetics , Autoimmune Diseases/genetics
SELECTION OF CITATIONS
SEARCH DETAIL